TY - JOUR T1 - Randomised controlled trial to investigate the use of high-frequency airway oscillations as <strong>t</strong>raining to <strong>i</strong>mprove <strong>d</strong>yspno<strong>e</strong>a (TIDe) in COPD JF - Thorax JO - Thorax SP - 690 LP - 696 DO - 10.1136/thoraxjnl-2021-217072 VL - 77 IS - 7 AU - Enya Daynes AU - Neil Greening AU - Sally J Singh Y1 - 2022/07/01 UR - http://thorax.bmj.com/content/77/7/690.abstract N2 - Background Chronic obstructive pulmonary disease (COPD) is characterised by symptomatic dyspnoea and reduced exercise tolerance, in part as a result muscle weakness, for which inspiratory muscle training (IMT) may be useful. Excess mucus hypersecretion commonly coexists in COPD and may lead to reduce ventilation, further impacting on breathlessness. Devices for sputum clearance may be employed to aid mucus expectoration. This trial aimed to explore the effectiveness of a combined IMT and high-frequency airway oscillating (HFAO) device in the management of dyspnoea.Methods This was a double-blinded, randomised sham-controlled trial which recruited symptomatic patients with COPD. Patients were randomised to either a HFAO device (Aerosure) or sham device for 8 weeks, three times a day. The primary outcome was the Chronic Respiratory Questionnaire dyspnoea (CRQ-D) domain. Pre-specified subgroup analyses were performed including those with respiratory muscle weakness, excessive sputum and frequent exacerbators.Results 104 participants (68% men, mean (SD) age 69.75 years (7.41), forced expiratory volume in 1 s per cent predicted 48.22% (18.75)) were recruited to this study with 96 participants completing. No difference in CRQ-D was seen between groups (0·28, 95% CI −0.19 to 0.75, p=0.24), though meaningful improvements were seen over time in both groups (mean (SD) HFAO 0.45 (0.78), p&lt;0.01; sham 0.73 (1.09), p&lt;0.01). Maximal inspiratory pressure significantly improved in the HFAO group over sham (5.26, 95% CI 0.34 to 10.19, p=0.05). Similar patterns were seen in the subgroup analysis.Conclusion There were no statistical differences between the HFAO and the sham group in improving dyspnoea measured by the CRQ-D.Trial registration number ISRCTN45695543.Data are available upon reasonable request. Data can be shared upon reasonable request, however individual patient data will not be shared. Statistical analysis plan and protocol can be shared upon request. ER -